SEC Form 4 · accession 0001209191-18-006226
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terrie Curran
Officer — See remarks
Period of report
Jan 29, 2018
Accepted (ET)
Jan 31, 2018 · 4:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $103.26 | Jan 29, 2018 | A | 6,777 | A | — | Jan 29, 2028 | Common Stock | 6,777 | 6,777 | D |
Explanation of responses
- F1Option is immediately exercisable and will vest as follows: 1,694 shares on January 29, 2019; 1,694 shares on January 29, 2020; 1,694 shares on January 29, 2021; and 1,695 shares on January 29, 2022.
- F2The option was issued pursuant to the Company's 2017 Stock Incentive Plan.
Remarks
President, Inflammation and Immunology